Point–Counterpoint: Screening and Surveillance for Barrett’s Esophagus, Is It Worthwhile?

Fouad Otaki, Prasad G. Iyer

Research output: Contribution to journalReview article

Abstract

The exponential rise in incidence of esophageal adenocarcinoma (EAC), paired with persistently poor survival, continues to drive efforts to improve and optimize screening and surveillance practices. While advancements in endoscopic therapy have generated a shift in management and significantly improved the outcomes of patients with early-stage EAC, the majority of prevalent EAC continues to be diagnosed at advanced stages, remaining ineligible for curative therapy. Barrett’s esophagus (BE) screening, when applied to high-yield target populations, using minimally or noninvasive accurate tests, followed by endoscopic surveillance to detect prevalent or incident dysplasia/EAC (which can then be treated successfully) is the cornerstone of the current BE management paradigm. While supported by some empiric evidence and attractive, this approach faces a number of challenges, which are also balanced by numerous recent advances in these areas. In this manuscript, we review the rationale, supportive evidence, current challenges, and recent progress in BE screening and surveillance.

Original languageEnglish (US)
Pages (from-to)2081-2093
Number of pages13
JournalDigestive diseases and sciences
Volume63
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Barrett Esophagus
Adenocarcinoma
Health Services Needs and Demand
Survival
Incidence
Therapeutics

Keywords

  • Barrett’s esophagus
  • Endoscopy
  • Esophageal cancer
  • Screening
  • Surveillance

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology

Cite this

Point–Counterpoint : Screening and Surveillance for Barrett’s Esophagus, Is It Worthwhile? / Otaki, Fouad; Iyer, Prasad G.

In: Digestive diseases and sciences, Vol. 63, No. 8, 01.08.2018, p. 2081-2093.

Research output: Contribution to journalReview article

@article{0a57b87491264e7685f455c96f0eba96,
title = "Point–Counterpoint: Screening and Surveillance for Barrett’s Esophagus, Is It Worthwhile?",
abstract = "The exponential rise in incidence of esophageal adenocarcinoma (EAC), paired with persistently poor survival, continues to drive efforts to improve and optimize screening and surveillance practices. While advancements in endoscopic therapy have generated a shift in management and significantly improved the outcomes of patients with early-stage EAC, the majority of prevalent EAC continues to be diagnosed at advanced stages, remaining ineligible for curative therapy. Barrett’s esophagus (BE) screening, when applied to high-yield target populations, using minimally or noninvasive accurate tests, followed by endoscopic surveillance to detect prevalent or incident dysplasia/EAC (which can then be treated successfully) is the cornerstone of the current BE management paradigm. While supported by some empiric evidence and attractive, this approach faces a number of challenges, which are also balanced by numerous recent advances in these areas. In this manuscript, we review the rationale, supportive evidence, current challenges, and recent progress in BE screening and surveillance.",
keywords = "Barrett’s esophagus, Endoscopy, Esophageal cancer, Screening, Surveillance",
author = "Fouad Otaki and Iyer, {Prasad G.}",
year = "2018",
month = "8",
day = "1",
doi = "10.1007/s10620-018-5065-9",
language = "English (US)",
volume = "63",
pages = "2081--2093",
journal = "American Journal of Digestive Diseases and Nutrition",
issn = "0163-2116",
publisher = "Plenum Publishers",
number = "8",

}

TY - JOUR

T1 - Point–Counterpoint

T2 - Screening and Surveillance for Barrett’s Esophagus, Is It Worthwhile?

AU - Otaki, Fouad

AU - Iyer, Prasad G.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - The exponential rise in incidence of esophageal adenocarcinoma (EAC), paired with persistently poor survival, continues to drive efforts to improve and optimize screening and surveillance practices. While advancements in endoscopic therapy have generated a shift in management and significantly improved the outcomes of patients with early-stage EAC, the majority of prevalent EAC continues to be diagnosed at advanced stages, remaining ineligible for curative therapy. Barrett’s esophagus (BE) screening, when applied to high-yield target populations, using minimally or noninvasive accurate tests, followed by endoscopic surveillance to detect prevalent or incident dysplasia/EAC (which can then be treated successfully) is the cornerstone of the current BE management paradigm. While supported by some empiric evidence and attractive, this approach faces a number of challenges, which are also balanced by numerous recent advances in these areas. In this manuscript, we review the rationale, supportive evidence, current challenges, and recent progress in BE screening and surveillance.

AB - The exponential rise in incidence of esophageal adenocarcinoma (EAC), paired with persistently poor survival, continues to drive efforts to improve and optimize screening and surveillance practices. While advancements in endoscopic therapy have generated a shift in management and significantly improved the outcomes of patients with early-stage EAC, the majority of prevalent EAC continues to be diagnosed at advanced stages, remaining ineligible for curative therapy. Barrett’s esophagus (BE) screening, when applied to high-yield target populations, using minimally or noninvasive accurate tests, followed by endoscopic surveillance to detect prevalent or incident dysplasia/EAC (which can then be treated successfully) is the cornerstone of the current BE management paradigm. While supported by some empiric evidence and attractive, this approach faces a number of challenges, which are also balanced by numerous recent advances in these areas. In this manuscript, we review the rationale, supportive evidence, current challenges, and recent progress in BE screening and surveillance.

KW - Barrett’s esophagus

KW - Endoscopy

KW - Esophageal cancer

KW - Screening

KW - Surveillance

UR - http://www.scopus.com/inward/record.url?scp=85050375701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050375701&partnerID=8YFLogxK

U2 - 10.1007/s10620-018-5065-9

DO - 10.1007/s10620-018-5065-9

M3 - Review article

C2 - 29713986

AN - SCOPUS:85050375701

VL - 63

SP - 2081

EP - 2093

JO - American Journal of Digestive Diseases and Nutrition

JF - American Journal of Digestive Diseases and Nutrition

SN - 0163-2116

IS - 8

ER -